SPRR1B

Across TCGA pan-cancer cohorts, SPRR1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPRR1B data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SPRR1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPRR1B expression acts as an unfavorable survival marker.

BLCA, SKCM, and LIHC are the cancer types where SPRR1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.205	0.618	.018	15	view →
SKCM	OS	Median	All	0.257	0.781	.015	9	view →
LIHC	OS	Median	All	0.008	0.775	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SPRR1B–BLCA (OS)

Open the BLCA breakdown →